KR20250081944A - 종양 살상 바이러스 및 이의 사용방법 - Google Patents

종양 살상 바이러스 및 이의 사용방법 Download PDF

Info

Publication number
KR20250081944A
KR20250081944A KR1020257017356A KR20257017356A KR20250081944A KR 20250081944 A KR20250081944 A KR 20250081944A KR 1020257017356 A KR1020257017356 A KR 1020257017356A KR 20257017356 A KR20257017356 A KR 20257017356A KR 20250081944 A KR20250081944 A KR 20250081944A
Authority
KR
South Korea
Prior art keywords
adsyn
cells
protein
adenovirus
rapamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257017356A
Other languages
English (en)
Korean (ko)
Inventor
클라대흐 오셔
시게키 미야케-스토너
Original Assignee
솔크 인스티튜트 포 바이올로지칼 스터디즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 솔크 인스티튜트 포 바이올로지칼 스터디즈 filed Critical 솔크 인스티튜트 포 바이올로지칼 스터디즈
Publication of KR20250081944A publication Critical patent/KR20250081944A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020257017356A 2014-09-24 2015-09-23 종양 살상 바이러스 및 이의 사용방법 Pending KR20250081944A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462054724P 2014-09-24 2014-09-24
US62/054,724 2014-09-24
KR1020237040919A KR102814615B1 (ko) 2014-09-24 2015-09-23 종양 살상 바이러스 및 이의 사용방법
PCT/US2015/051745 WO2016049201A1 (en) 2014-09-24 2015-09-23 Oncolytic tumor viruses and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237040919A Division KR102814615B1 (ko) 2014-09-24 2015-09-23 종양 살상 바이러스 및 이의 사용방법

Publications (1)

Publication Number Publication Date
KR20250081944A true KR20250081944A (ko) 2025-06-05

Family

ID=55581955

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237040919A Active KR102814615B1 (ko) 2014-09-24 2015-09-23 종양 살상 바이러스 및 이의 사용방법
KR1020177011121A Active KR102608590B1 (ko) 2014-09-24 2015-09-23 종양 살상 바이러스 및 이의 사용방법
KR1020257017356A Pending KR20250081944A (ko) 2014-09-24 2015-09-23 종양 살상 바이러스 및 이의 사용방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020237040919A Active KR102814615B1 (ko) 2014-09-24 2015-09-23 종양 살상 바이러스 및 이의 사용방법
KR1020177011121A Active KR102608590B1 (ko) 2014-09-24 2015-09-23 종양 살상 바이러스 및 이의 사용방법

Country Status (11)

Country Link
US (1) US20170202893A1 (enExample)
EP (2) EP4043021A3 (enExample)
JP (3) JP6764859B2 (enExample)
KR (3) KR102814615B1 (enExample)
CN (1) CN108064275A (enExample)
AU (3) AU2015320665B2 (enExample)
CA (1) CA2961748A1 (enExample)
DK (1) DK3198009T3 (enExample)
ES (1) ES2899913T3 (enExample)
PL (1) PL3198009T3 (enExample)
WO (1) WO2016049201A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
ES2899913T3 (es) * 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
WO2017062511A1 (en) * 2015-10-05 2017-04-13 Salk Instutitute For Biological Studies Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR20220163505A (ko) * 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
AU2017375633C1 (en) * 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018125970A1 (en) * 2016-12-30 2018-07-05 Salk Institute For Biological Studies Synthetic adenoviruses targeting bone tissue and uses thereof
SG11201906973TA (en) * 2017-01-30 2019-08-27 Epicentrx Inc Multiple transgene recombinant adenovirus
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
WO2019191494A1 (en) * 2018-03-28 2019-10-03 Epicentrx, Inc. Personalized cancer vaccines
CN112292449A (zh) * 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
CN111363726A (zh) * 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用
JP2022521268A (ja) * 2019-02-21 2022-04-06 アンリーシュ イミュノ オンカリティクス，インコーポレイテッド 腫瘍溶解性アデノウイルスベクター及び使用法
US20220354911A1 (en) * 2019-09-05 2022-11-10 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
EP3812465A1 (en) 2019-10-21 2021-04-28 Universität Ulm Adenovirus comprising a modified adenovirus hexon protein
JP2023513794A (ja) * 2020-02-14 2023-04-03 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｕｌｋ１／２の阻害剤およびその使用方法
AU2021306714A1 (en) * 2020-07-06 2023-02-02 Salk Institute For Biological Studies Oncolytic adenovirus with replication selectivity based on status of p53 transcriptional activity
WO2022236080A2 (en) * 2021-05-06 2022-11-10 Asimov Inc. Compositions and methods for adeno-associated viral production

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
EP1702071B1 (en) * 2003-12-31 2012-02-22 Kalobios Inc. Transactivation system for mammalian cells
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
JP5981916B2 (ja) * 2010-08-16 2016-09-07 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの構築方法
JP6170999B2 (ja) * 2012-03-13 2017-07-26 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスおよび化学二量体を用いる選択細胞の標的化
JP6576326B2 (ja) * 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
SG10202004535PA (en) * 2013-04-18 2020-06-29 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso

Also Published As

Publication number Publication date
EP4043021A2 (en) 2022-08-17
KR20230165385A (ko) 2023-12-05
KR20170063801A (ko) 2017-06-08
AU2025203440A1 (en) 2025-06-05
EP3198009B1 (en) 2021-09-08
CA2961748A1 (en) 2016-03-31
KR102814615B1 (ko) 2025-05-28
KR102608590B1 (ko) 2023-12-01
CN108064275A (zh) 2018-05-22
JP2024038030A (ja) 2024-03-19
PL3198009T3 (pl) 2022-01-24
AU2015320665B2 (en) 2022-06-16
EP4043021A3 (en) 2022-11-23
EP3198009A4 (en) 2018-09-05
AU2015320665A1 (en) 2017-04-06
WO2016049201A1 (en) 2016-03-31
ES2899913T3 (es) 2022-03-15
JP2021007392A (ja) 2021-01-28
AU2022203504A1 (en) 2022-06-09
US20170202893A1 (en) 2017-07-20
AU2022203504B2 (en) 2025-02-20
JP7416423B2 (ja) 2024-01-17
EP3198009A1 (en) 2017-08-02
JP2017534263A (ja) 2017-11-24
JP6764859B2 (ja) 2020-10-07
DK3198009T3 (da) 2021-11-22

Similar Documents

Publication Publication Date Title
AU2022203504B2 (en) Oncolytic tumor viruses and methods of use
KR102471633B1 (ko) 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
AU2011332025B2 (en) Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
KR101614364B1 (ko) 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
KR101957616B1 (ko) 아데노바이러스 조립 방법
KR101761425B1 (ko) 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
AU2020281047B2 (en) High throughput assay for measuring adenovirus replication kinetics
AU2019251356B2 (en) Oncolytic adenovirus compositions with enhanced replication properties
HK1252010A1 (zh) 猴腺病毒(大猩猩)或腺病毒载体及其使用方法
AU2017305176B2 (en) Compositions and methods of replication deficient adenoviral vectors for vaccine applications
KR20100109914A (ko) 유인원 아과 ｂ 아데노바이러스 ｓａｄｖ-28,27,-29,-32,-33, 및 -35 및 그것의 사용
CN107574154A (zh) 猴(大猩猩)腺病毒或腺病毒载体及其使用方法
CN112011570B (zh) 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用
KR20230008069A (ko) 아데노바이러스 발현 벡터, 및 제조를 위한 방법 및 세포주
CN116323955A (zh) 通过crispr/cas介导的体内末端解析拯救重组腺病毒
CN114262692A (zh) 一种携带tmvp1和hsv-tk的溶瘤腺病毒重组体，其构建方法及应用
CN114231504A (zh) 一种携带tmtp1和hsv-tk的溶瘤腺病毒重组体、其构建方法及应用
RU2829510C2 (ru) Онколитические аденовирусные композиции с улучшенными репликационными свойствами
KR102808930B1 (ko) 복제가능 아데노바이러스를 포함하지 않는 신규 아데노바이러스 벡터 및 이의 용도
RU2821989C1 (ru) Новый аденовирусный вектор, не включающий компетентный по репликации аденовирус, и его применение
NL2023464B1 (en) Oncolytic Non-human adenoviruses and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250526

Application number text: 1020237040919

Filing date: 20231127

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250625

Comment text: Request for Examination of Application